Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)

B. D. Cheson, N. L. Bartlett, J. M. Vose, A. Lopez-Hernandez, A. L. Seiz, A. T. Keating, S. Shamsili, K. P. Papadopoulos, Kyriakos P. Papadopoulos

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Erratum: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma (Cancer DOI: 10.1002/cncr.26510)'. Together they form a unique fingerprint.